Breaking News
June 1, 2007
Millennium Pharmaceuticals has appointed three members to its executive management team: chief scientific officer Joseph Bolen, Ph.D., chief medical officer Nancy Simonian, M.D., and senior vice president of non-clinical development sciences Peter Sm…
Read More »
June 1, 2007
Immunicon Corp. has entered into a research services agreement with Bristol-Myers Squibb (BMS) involving protein and molecular targets associated with circulating tumor cells (CTCs).
Leon Terstappen, M.D., Ph.D., chief scientific officer of Immu…
Read More »
June 1, 2007
Roberto J. Bitton, M.D. has been appointed project leader, Latin America, Kendle. In this role, he will provide medical and therapeutic expertise for Phase I-IV clinical development projects for the company's biopharmaceutical customers, with an emp…
Read More »
May 31, 2007
The FDA has accepted for review an NDA from Progenics Pharmaceuticals and Wyeth for subcutaneous methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients receiving palliative care. The FDA has set a Prescription Drug User F…
Read More »
May 31, 2007
MDS Pharma Services has named Dr. Todd Johnson to the position of senior vice-president for Strategy and Corporate Development. He will lead efforts to accelerate profitable growth through strategic partnerships and acquisitions. Before joining MDS,…
Read More »
May 31, 2007
Wyeth has received FDA approval to market Torisel for patients with advanced renal cell carcinoma (RCC). Torisel is the first targeted renal cancer therapy proven to extend median overall survival versus interferon- alpha, an active comparator, in th…
Read More »
May 30, 2007
Novacea, Inc. and Schering-Plough have entered into an exclusive worldwide license agreement for the development and commercialization of Asentar, a novel, proprietary, high-dose oral formulation of calcitriol, a potent hormone that exerts its effect…
Read More »
May 30, 2007
Valeant Pharmaceuticals International has appointed Parexel International to develop, coordinate and prepare the New Drug Application (NDA) and the European Marketing Authorization Application (MAA) for Valeant's investigational compound retigabine.…
Read More »
May 30, 2007
Human Genome Sciences and GlaxoSmithKline have begun dosing for BLISS-52, the second of two Phase III trials of LymphoStat-B in patients with active systemic lupus erythematosus (SLE). Dosing in BLISS-76, the first Phase III trial of the drug, began…
Read More »
May 29, 2007
Genzyme Corp. has announced that it will buy Bioenvision, Inc. for approximately $345 million in cash. The purchase, which has unanimous support from Bioenvision's board, will enhance Genzyme's oncology business by yielding exclusive, worldwide right…
Read More »
May 29, 2007
Exelixis, Inc. has appointed Arthur DeCillis, M.D. to the position of vice president, clinical research, and Anne Champsaur, M.D. to the position of vice president, drug safety. Both appointees will report to Gisela M. Schwab, M.D., senior vice presi…
Read More »
May 29, 2007
Asuragen, Inc., an oncology molecular diagnostic company and molecular biology service provider, was selected to provide GLP compliant laboratory testing to assist in gene expression studies being conducted by Millennium Pharmaceuticals of Cambridge,…
Read More »
May 29, 2007
Draxis Pharma, the contract manufacturing division of Draxis Health Inc., has appointed Bruce DeChambre as vice president commercial and business development. Mr. DeChambre's responsibilities include identifying prospective customers and developing n…
Read More »
May 25, 2007
Dr. Frank Deane has been promoted to president, manufacturing at Lilly from his current role of vice president, quality. He will succeed Scott Canute, who has led the manufacturing organization since 2001. Mr. Canute, after six years of leading a tra…
Read More »
May 24, 2007
Novartis and Nordic Biosciences have begun a Phase III clinical program of oral salmon calcitonin (SMC021) for the treatment of osteoarthritis, a chronic, irreversible and degenerative condition. SMC021 is a new drug candidate with potential to be th…
Read More »
